Skip to main content
Boy with Bike

Our Patients

Our Promise to Patients

At CSL, we are Driven by Our Promise and guided by our values: Patient Focus, Innovation, Integrity, Collaboration and Superior Performance.

CSL is committed to putting patients first in everything we do to discover, develop and deliver biotherapies and vaccines that meet their needs.

We know that every patient is someone's child, parent, grandparent, family member, friend or colleague. We also understand that rare and serious diseases affect more than just the patient. They also impact their loved ones and the communities that support them.

With that in mind, we strive to provide therapies that meet patients' needs, as well as build support systems to create empowerment and community through various programs and activities around the world. We also partner with patient advocacy organizations to improve and expand outreach, education, and access to medications and resources.

Our patients are our passion and that drives the way we work. We are committed to full transparency of expectations and results when partnering with them. We listen carefully to patients about their experiences and collaborate with them from initial research to delivery of our innovative medicines. We seek to fully understand their challenges to ensure our research is relevant, meaningful and leads to therapies that generate outcomes that matter to them and make a difference in their lives.

Our people are the heart of our patient-centric culture and we strive to earn the trust of our patients every day. CSL employees understand that they are personally responsible for ensuring that our interactions with patients are responsible, respectful and humble. We recognize patients as experts in how diseases affect their lives and actively seek their insights to guide our efforts.

Our people's commitment to patient-centricity as part of our values-based culture is essential to delivering on our promise to patients.

How can we help you?

Immunodefiency & Autoimmune Diseases

We offer one of the most comprehensive portfolios of high-quality, technically advanced immunoglobulin (Ig) therapies and we are the leading Ig manufacturer in the world. Treatments are available for the following conditions:

  • Primary Immunodeficiency
  • Secondary immunodeficiency
  • Chronic inflammatory demyelinating polyneuropathy (CIDP)
  • Immune Thrombocytopenia (ITP)
  • Kawasaki disease
  • Guillain-Barré syndrome (GBS)

 

Hereditary Bleeding Disorders

We are a world leader in innovative medicines for the treatment of bleeding disorders. We offer the largest portfolio for the treatment of hereditary bleeding disorders with more than a dozen plasma-derived and recombinant coagulation factor concentrates. Treatments are available for the following conditions:

  • Hemophilia A
  • Hemophilia B
  • von Willebrand disease
  • Factor XIII deficiency
  • Factor X deficiency
  • Fibrinogen deficiency

Hereditary Angioedema (HAE)

We recently introduced the world's first subcutaneous preventative treatment for attacks of Hereditary Angioedema (HAE), while still offering our intravenous C1-esterase inhibitor therapy for on-demand treatment.